[006] Given MALT-1's role as a modulator of the NF-κB pathway, which plays a central role in diseases including ABC-DLBCL, there is a need for compounds that inhibit MALT-1 protease activity for their use as anti-ABC-DLBCL therapies. In particular, there is a need for MALT-1 compounds that inhibit MALT-1 protease activity that have improved pharmaceutical properties.

SUMMARY

[007] In one aspect, the present disclosure provides for compounds of Formula (I), or a pharmaceutically acceptable salt thereof,



(I)

wherein:

R^{1a} is selected from the group consisting of OCH_3 and CH_3;

R^{1b} is selected from the group consisting of CH_3, CHF_2, and CF_3;

R^2 is selected from the group consisting of H and F;

R^3 is selected from the group consisting of H and F;

R^4 is selected from the group consisting of CHF_2 and CF_3;

R^5 is C_1-C_4 alkyl;

Ring A is a ring selected from the group consisting of  and ;

R^6 is selected from the group consisting of C_1-C_4 alkyl and C_1-C_4 hydroxyalkyl;

R^7 is selected from the group consisting of H and C_1-C_4 alkyl; and

R^8 is selected from the group consisting of CHF_2 and CH_3.

[008] In another aspect, Ring A is . In another aspect, R^2 is H. In another

1-acetyl-*N*-{(1*S*)-1-[4-({7-[(1*S*)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-*b*]pyridin-6-yl}amino)phenyl]-2,2,2-trifluoroethyl}-*N*-methylpiperidine-4-carboxamide;

1-(hydroxyacetyl)-*N*-methyl-*N*-{(1*S*)-2,2,2-trifluoro-1-[4-({7-[(1*R*)-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-*b*]pyridin-6-yl}amino)phenyl]ethyl}piperidine-4-carboxamide;

1-acetyl-*N*-methyl-*N*-{(1*S*)-2,2,2-trifluoro-1-[4-({7-[(1*R*)-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-*b*]pyridin-6-yl}amino)phenyl]ethyl}piperidine-4-carboxamide;

N-{(1*S*)-2,2-difluoro-1-[4-({2-methyl-7-[(1*R*)-2,2,2-trifluoro-1-methoxyethyl][1,3]thiazolo[5,4-*b*]pyridin-6-yl}amino)phenyl]ethyl}-1-(hydroxyacetyl)-*N*-methylpiperidine-4-carboxamide;

1-acetyl-*N*-{(1*S*)-2,2-difluoro-1-[4-({2-methyl-7-[(1*R*)-2,2,2-trifluoro-1-methoxyethyl][1,3]thiazolo[5,4-*b*]pyridin-6-yl}amino)phenyl]ethyl}-*N*-methylpiperidine-4-carboxamide;

N-methyl-1,1-dioxo-*N*-{(1*S*)-2,2,2-trifluoro-1-[4-({2-methyl-7-[(2*R*)-1,1,1-trifluoropropan-2-yl][1,3]thiazolo[5,4-*b*]pyridin-6-yl}amino)phenyl]ethyl}-1λ^6-thiane-4-carboxamide; and

N-methyl-1,1-dioxo-*N*-{(1*S*)-2,2,2-trifluoro-1-[4-({2-methyl-7-[(2*S*)-1,1,1-trifluoropropan-2-yl][1,3]thiazolo[5,4-*b*]pyridin-6-yl}amino)phenyl]ethyl}-1λ^6-thiane-4-carboxamide; or a pharmaceutically acceptable salt thereof.

[0011] In another aspect, the compound is *N*-{(1*S*)-1-[4-({7-[(1*R*)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-*b*]pyridin-6-yl}amino)phenyl]-2,2,2-trifluoroethyl}-*N*-methyl-1,1-dioxo-1λ^6-thiane-4-carboxamide, or a pharmaceutically acceptable salt thereof.

[0012] In another aspect, the compound is *N*-{(1*S*)-1-[4-({7-[(1*R*)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-*b*]pyridin-6-yl}amino)phenyl]-2,2,2-trifluoroethyl}-*N*-methyl-1,1-dioxo-1λ^6-thiane-4-carboxamide.

[0012a] In another aspect, provided herein is *N*-{(1*S*)-1-[4-({7-[(1*R*)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-*b*]pyridin-6-yl}amino)phenyl]-2,2,2-trifluoroethyl}-*N*-methyl-1,1-dioxo-1λ^6-thiane-4-carboxamide; or a pharmaceutically acceptable salt thereof.

[0012b] In another aspect, provided herein is *N*-{(1*S*)-1-[4-({7-[(1*R*)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-*b*]pyridin-6-yl}amino)phenyl]-2,2,2-trifluoroethyl}-*N*-

methyl-1,1-dioxo-1λ^6-thiane-4-carboxamide.

[0013] In another aspect, the present disclosure provides for a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) according to any of the preceding aspects, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

[0014] In another aspect, the present disclosure provides for a method for treating activated

WE CLAIM:

1. *N*-{(1*S*)-1-[4-({7-[(1*R*)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-*b*]pyridin-6-yl}amino)phenyl]-2,2,2-trifluoroethyl}-*N*-methyl-1,1-dioxo-1λ^6-thiane-4-carboxamide; or a pharmaceutically acceptable salt thereof.

2. *N*-{(1*S*)-1-[4-({7-[(1*R*)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-*b*]pyridin-6-yl}amino)phenyl]-2,2,2-trifluoroethyl}-*N*-methyl-1,1-dioxo-1λ^6-thiane-4-carboxamide.